VistaGen Therapeutics (NASDAQ:VTGN) Announces Earnings Results

VistaGen Therapeutics (NASDAQ:VTGN) issued its quarterly earnings results on Thursday. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06, Zacks reports. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.14 million.

VistaGen Therapeutics Stock Down 4.8%

Shares of VistaGen Therapeutics stock traded down $0.03 on Thursday, hitting $0.55. The stock had a trading volume of 1,686,332 shares, compared to its average volume of 1,233,242. VistaGen Therapeutics has a one year low of $0.50 and a one year high of $5.14. The stock’s 50-day simple moving average is $1.32 and its two-hundred day simple moving average is $2.84. The stock has a market cap of $21.52 million, a price-to-earnings ratio of -0.29 and a beta of 0.32.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP increased its position in shares of VistaGen Therapeutics by 223.5% in the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after acquiring an additional 199,958 shares during the period. Jane Street Group LLC purchased a new position in VistaGen Therapeutics during the 2nd quarter valued at about $190,000. Dimensional Fund Advisors LP raised its position in VistaGen Therapeutics by 123.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 151,874 shares of the company’s stock valued at $101,000 after purchasing an additional 83,857 shares during the last quarter. Geode Capital Management LLC raised its position in VistaGen Therapeutics by 18.3% during the 4th quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock valued at $234,000 after purchasing an additional 54,556 shares during the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new stake in VistaGen Therapeutics in the 3rd quarter worth approximately $152,000. Institutional investors own 78.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Jefferies Financial Group reissued a “hold” rating and issued a $0.90 target price (down previously from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research note on Wednesday, December 17th. Finally, William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, VistaGen Therapeutics presently has a consensus rating of “Reduce” and a consensus target price of $0.95.

Key VistaGen Therapeutics News

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Q3 FY2026 results beat expectations — VistaGen reported a narrower loss (reported EPS -$0.45 vs. consensus -$0.51) and revenue of $0.30M vs. consensus $0.14M, showing slightly better operating performance than expected. This can be viewed as a short‑term positive fundamental datapoint. View Press Release
• Positive Sentiment: Short interest decreased sharply in January (down ~16.6% to ~2.04M shares, ~5.3% of float), which may reduce immediate upward pressure from short‑covering volatility and slightly lessen selling pressure driven by shorts. (Data note: days‑to‑cover ~1.9.)
• Neutral Sentiment: Corporate update on PALISADE‑3 — the company said it reviewed available data from PALISADE‑3 and has implemented “moderate refinements” (statement truncated in the release). The lack of full detail makes the near‑term impact unclear — could reflect protocol/analysis changes or preparations for regulatory interactions. Investors should watch for the full BusinessWire update and follow‑up disclosures. Vistagen Reports Q3 FY2026 Results and Corporate Update
• Negative Sentiment: Multiple securities‑class‑action notices and filings — several law firms (Pomerantz, Bernstein Liebhard, Rosen, Levi & Korsinsky, Faruqi & Faruqi, The Gross Law Firm, etc.) have announced investigations or reminded investors of lead‑plaintiff deadlines (March 16, 2026). This increases legal and reputational risk, can drive selling pressure, and typically elevates volatility for the stock. Pomerantz Investor Alert

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.